future of protein production with plates with healthy food and protein

Amyris to acquire Oobli as it expands into sweet proteins

November 17, 2026

Amyris has agreed to acquire sweet protein developer Oobli, combining its strain engineering and biomanufacturing capabilities with a fermentation-derived ingredient portfolio designed to help food and beverage manufacturers reduce sugar.

• Amyris announced the planned Oobli acquisition on November 12.
• The deal adds brazzein, monellin and thaumatin technologies.
• Existing customer commitments and partnerships will continue uninterrupted.

The transaction is expected to close in the coming weeks, according to the announcement. Financial terms were not disclosed.

“In Oobli, we see a commercial and technology platform that is a great complement to our own,” says Kathy Fortmann, Chief Executive Officer of Amyris.

“Oobli is poised to transform how sweetness makes it to market, and we are thrilled to bring our commercial scale and resources to further accelerate the sweet revolution.”

Oobli has spent the past decade developing fermentation processes for proteins naturally found in fruits and berries. Its portfolio includes Oubli Fruit Sweet Protein, Serendipity Berry Sweet Protein and Katemfe Fruit Sweet Protein, scientifically known as brazzein, monellin and thaumatin, respectively.

The ingredients are hundreds to thousands of times sweeter than sugar, allowing food developers to achieve sweetness at low inclusion levels. Oobli markets them for applications including beverages, dairy, sports nutrition, chocolate, bakery and confectionery.

Their role is sweetening rather than protein enrichment. Oobli explains that the small quantities required to sweeten a product do not make them a substantial source of dietary protein.

The planned acquisition follows Amyris’ expansion of manufacturing capacity at its fermentation facility in Barra Bonita, Brazil, earlier this year. Amyris says the deal will extend its commercial and technical capabilities in protein- and peptide-based ingredients, with Oobli’s existing sweet protein portfolio the first to benefit from the combined platform.

Fortmann also identifies opportunities outside food and beverages, including personal care, flavors and fragrances, and agriculture. The acquisition brings Oobli’s protein fermentation expertise into a business already producing specialty molecules for multiple industries.

“Further, by bringing Oobli’s protein expertise together with our strain engineering, manufacturing scale, and commercial capabilities, we see the potential to broaden our capabilities in food and beverage, personal care, flavor and fragrances, agriculture, and beyond, expanding the ways we can help customers innovate,” she says.

Oobli’s regulatory position varies across the portfolio. The US Food and Drug Administration has issued “no questions” responses to its Generally Recognized as Safe notifications for brazzein and monellin. The agency’s public inventory lists Oobli’s thaumatin II notification as pending.

Separately, Oobli lists all three protein types as FEMA GRAS-affirmed for specified flavor uses. That assessment concerns use as flavor ingredients and is distinct from the FDA’s review of GRAS notifications for sweetening applications.

“At Oobli, we have always believed there was a better way to deliver the sweet taste consumers love, without the trade-offs to health and our environment. It is with immense pride that we look back on the breakthroughs we have achieved,” says Ali Wing, Chief Executive Officer of Oobli.

“Joining forces with Amyris gives us the scale and resources to realize our ambition of making sweet proteins the global standard in sweetness solutions. Sweet proteins are an idea whose time is now.”

The companies identify sugar reduction and consumer interest in metabolic health as commercial drivers for the portfolio. Oobli’s business includes its Oobli Inside platform, through which food and beverage companies incorporate sweet proteins into products.

Amyris says the proposed combination will connect that ingredient and application expertise with its scientific resources, strain development and manufacturing capabilities.

“At Amyris, we’ve seen that biomanufactured solutions win when they align with consumer demand and market needs,” Fortmann says.

Amyris says all existing Oobli customer commitments and brand partnerships will continue to be honored without interruption as the acquisition proceeds.

Meta description: Amyris plans to acquire Oobli, combining sweet protein ingredients for sugar reduction with its strain engineering and biomanufacturing capabilities.

‍If you liked this, check these out...

• Deep Dive: Breakout bets‍
• Amai Proteins secures FDA ‘no questions’ letter for ‘sweelin’ sweet protein, clearing path to US commercialization‍
• Amai Proteins’ sweelin approved in Singapore as precision fermentation sweet protein

Join Us At One Of Our Upcoming Events

If you have any questions or would like to get in touch with us, please email info@futureofproteinproduction.com

About the Speaker

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.